Sulopenem (CP-70,429) is a thiopenemantibiotic derivative from thepenem family, which unlike most related drugs is orally active. It was developed in Japan in the 1990s, and has been approved to treat uncomplicated urinary tract infections in combination withprobenecid (brand name Orlynvah). It has reached Phase IIIclinical trials on several occasions and continues to be the subject of ongoing research into potential applications, especially in the treatment ofmultiple drug resistanturinary tract infections.[1][2][3][4][5]
In October 2024, the US Food and Drug Administration approved sulopenem etzadroxil with probenecid combination for the treatment of urinary tract infections caused byEscherichia coli,Klebsiella pneumoniae, orProteus mirabilis in adult women with limited alternative oral antibiotic options.[6]
^Hamilton-Miller JM (November 2003). "Chemical and microbiologic aspects of penems, a distinct class of beta-lactams: focus on faropenem".Pharmacotherapy.23 (11):1497–1507.doi:10.1592/phco.23.14.1497.31937.PMID14620395.S2CID43705118.
^Bader MS, Loeb M, Leto D, Brooks AA (April 2020). "Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents".Postgraduate Medicine.132 (3):234–250.doi:10.1080/00325481.2019.1680052.PMID31608743.S2CID204545734.
